These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 15604893)

  • 1. Prognostic factors in acute myeloid leukemia.
    Avivi I; Rowe JM
    Curr Opin Hematol; 2005 Jan; 12(1):62-7. PubMed ID: 15604893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pre-transplantation minimal residual disease with cytogenetic and molecular diagnostic features improves risk stratification in acute myeloid leukemia.
    Oran B; Jorgensen JL; Marin D; Wang S; Ahmed S; Alousi AM; Andersson BS; Bashir Q; Bassett R; Lyons G; Chen J; Rezvani K; Popat U; Kebriaei P; Patel K; Rondon G; Shpall EJ; Champlin RE
    Haematologica; 2017 Jan; 102(1):110-117. PubMed ID: 27540139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic implications of genetic aberrations in acute myelogenous leukemia with normal cytogenetics.
    Ghanem H; Tank N; Tabbara IA
    Am J Hematol; 2012 Jan; 87(1):69-77. PubMed ID: 22072438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute myeloid leukemia: 2013 update on risk-stratification and management.
    Estey EH
    Am J Hematol; 2013 Apr; 88(4):318-27. PubMed ID: 23526416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular heterogeneity and prognostic biomarkers in adults with acute myeloid leukemia and normal cytogenetics.
    Marcucci G; Mrózek K; Bloomfield CD
    Curr Opin Hematol; 2005 Jan; 12(1):68-75. PubMed ID: 15604894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Digital droplet PCR-based absolute quantification of pre-transplant NPM1 mutation burden predicts relapse in acute myeloid leukemia patients.
    Bill M; Grimm J; Jentzsch M; Kloss L; Goldmann K; Schulz J; Beinicke S; Häntschel J; Cross M; Vucinic V; Pönisch W; Behre G; Franke GN; Lange T; Niederwieser D; Schwind S
    Ann Hematol; 2018 Oct; 97(10):1757-1765. PubMed ID: 29785446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Residual disease detected by multidimensional flow cytometry shows prognostic significance in childhood acute myeloid leukemia with intermediate cytogenetics and negative FLT3-ITD: a report from the Tokyo Children's Cancer Study Group.
    Keino D; Kinoshita A; Tomizawa D; Takahashi H; Ida K; Kurosawa H; Koike K; Ota S; Iwasaki N; Fujimura J; Yuza Y; Kiyotani C; Yamamoto S; Osumi T; Ueda T; Mochizuki S; Isoyama K; Hanada R; Tawa A; Manabe A; Toguchi Y; Ohara A
    Int J Hematol; 2016 Apr; 103(4):416-22. PubMed ID: 26781613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Minimal/Measurable Residual Disease Monitoring in
    Forghieri F; Comoli P; Marasca R; Potenza L; Luppi M
    Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30404199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive factors of relapse and survival in childhood acute myeloid leukemia: role of minimal residual disease.
    Rizzari C; Cazzaniga G; Coliva T; De Angelis C; Conter V
    Expert Rev Anticancer Ther; 2011 Sep; 11(9):1391-401. PubMed ID: 21929313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of immunophenotyping and gene mutations in elderly patients with acute myeloid leukemia with normal karyotype.
    Dang H; Jiang A; Kamel-Reid S; Brandwein J; Chang H
    Hum Pathol; 2013 Jan; 44(1):55-61. PubMed ID: 22939316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular Minimal Residual Disease in Acute Myeloid Leukemia.
    Jongen-Lavrencic M; Grob T; Hanekamp D; Kavelaars FG; Al Hinai A; Zeilemaker A; Erpelinck-Verschueren CAJ; Gradowska PL; Meijer R; Cloos J; Biemond BJ; Graux C; van Marwijk Kooy M; Manz MG; Pabst T; Passweg JR; Havelange V; Ossenkoppele GJ; Sanders MA; Schuurhuis GJ; Löwenberg B; Valk PJM
    N Engl J Med; 2018 Mar; 378(13):1189-1199. PubMed ID: 29601269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The expression level of BAALC-associated microRNA miR-3151 is an independent prognostic factor in younger patients with cytogenetic intermediate-risk acute myeloid leukemia.
    Díaz-Beyá M; Brunet S; Nomdedéu J; Cordeiro A; Tormo M; Escoda L; Ribera JM; Arnan M; Heras I; Gallardo D; Bargay J; Queipo de Llano MP; Salamero O; Martí JM; Sampol A; Pedro C; Hoyos M; Pratcorona M; Castellano JJ; Nomdedeu M; Risueño RM; Sierra J; Monzó M; Navarro A; Esteve J
    Blood Cancer J; 2015 Oct; 5(10):e352. PubMed ID: 26430723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of CEBPA mutations and BAALC expression in acute myeloid leukemia Egyptian patients with normal karyotype.
    El-Sharnouby JA; Ahmed LM; Taha AM; Kamal O
    Egypt J Immunol; 2008; 15(1):131-43. PubMed ID: 20306678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of minimal residual disease (MRD) monitoring by WT1 quantification between childhood acute myeloid leukemia and acute lymphoblastic leukemia.
    Zhang R; Yang JY; Sun HQ; Jia H; Liao J; Shi YJ; Li G
    Eur Rev Med Pharmacol Sci; 2015; 19(14):2679-88. PubMed ID: 26221900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical characteristics and prognosis of acute myeloid leukemia associated with DNA-methylation regulatory gene mutations.
    Ryotokuji T; Yamaguchi H; Ueki T; Usuki K; Kurosawa S; Kobayashi Y; Kawata E; Tajika K; Gomi S; Kanda J; Kobayashi A; Omori I; Marumo A; Fujiwara Y; Yui S; Terada K; Fukunaga K; Hirakawa T; Arai K; Kitano T; Kosaka F; Tamai H; Nakayama K; Wakita S; Fukuda T; Inokuchi K
    Haematologica; 2016 Sep; 101(9):1074-81. PubMed ID: 27247325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Acute leukemia in adults].
    Eigendorff E; Hochhaus A
    Pathologe; 2015 Sep; 36(5):503-17; quiz 518-9. PubMed ID: 26314268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pretransplant NPM1 MRD levels predict outcome after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia.
    Kayser S; Benner A; Thiede C; Martens U; Huber J; Stadtherr P; Janssen JW; Röllig C; Uppenkamp MJ; Bochtler T; Hegenbart U; Ehninger G; Ho AD; Dreger P; Krämer A
    Blood Cancer J; 2016 Jul; 6(7):e449. PubMed ID: 27471865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interest of cytogenetic and FISH evaluation for prognosis evaluation in 198 patients with acute myeloid leukemia in first complete remission in a single institution.
    Hirsch P; Labopin M; Viguié F; Perot C; Isnard F; Mamez AC; Bilhou-Nabera C; Marzac C; Delhommeau F; Lapusan S; Marie JP; Mohty M; Legrand O
    Leuk Res; 2014 Aug; 38(8):907-12. PubMed ID: 24957411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A >or=1 log rise in RQ-PCR transcript levels defines molecular relapse in core binding factor acute myeloid leukemia and predicts subsequent morphologic relapse.
    Lane S; Saal R; Mollee P; Jones M; Grigg A; Taylor K; Seymour J; Kennedy G; Williams B; Grimmett K; Griffiths V; Gill D; Hourigan M; Marlton P
    Leuk Lymphoma; 2008 Mar; 49(3):517-23. PubMed ID: 18297529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene expression with prognostic implications in cytogenetically normal acute myeloid leukemia.
    Baldus CD; Bullinger L
    Semin Oncol; 2008 Aug; 35(4):356-64. PubMed ID: 18692686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.